Document is current
Any future updates will be listed below
-
Authors
Truijen, Saskia P. M. https://orcid.org/0000-0003-1252-5026
Boonen, Annelies https://orcid.org/0000-0003-0682-9533
Ramiro, Sofia https://orcid.org/0000-0002-8899-9087
van Onna, Marloes https://orcid.org/0000-0001-5535-3119
-
Funding
Funding for this research was provided by:
Pfizer (Pfizer)
ReumaNederland (ReumaNederland)
- License Information
-
More Information
Article History
Received: 15 March 2026
Accepted: 1 June 2026
First Online: 17 June 2026
Declarations
Conflict of interest: S.P.M.T. declares that she has no conflicts of interest. AB has received to her department research grants from AbbVie and Celgene and consultancy fees from UCB, Eli Lilly, Novartis, Sandoz and Alfasigma. SR has received research grants and/or consultancy fees from AbbVie, Alfasigma, Eli Lilly, MSD, Novartis, Pfizer, Takeda, and UCB and is a member of the Executive Committee of the Assessment of Spondyloarthritis international society and of the EULAR Quality of Care Committee. MO has received to her department consultancy fees from Novartis, Pfizer and Alfasigma. Research grant: Pfizer and ReumaNederland. This study was funded by Pfizer and the Dutch Arthritis Society (ReumaNederland), who had no role in the design, conduct, analysis, or reporting of the study.
Disclaimer: No part of this report is copied or published elsewhere in whole or in part.
Declaration of generative AI and AI-assisted technologies in the manuscript preparation process: During the preparation of this work the author(s) used ChatGPT (OpenAI) in order to rephrase sentences and refining spelling and grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.
